Literature DB >> 14501613

Hepatitis C virus RNA load in relapsed patients: week two of treatment is the best time to predict the complete response.

Philippe Halfon1, Hacene Khiri, Albert Tran, Guillaume Pénaranda, Jerome Courcambeck, Hélene Joly, Denis Ouzan.   

Abstract

OBJECTIVE: An early virological response has been shown to be predictive of a sustained virological response to antiviral treatment in chronic hepatitis C infection. The aim of the study was to analyse viral kinetics during the first 6 weeks of treatment (interferon plus ribavirin) in 18 relapsed hepatitis C patients after a first course of interferon monotherapy.
METHODS: We studied 18 relapsed patients treated with interferon and ribavirin. A sustained virological response (negative HCV RNA measured by polymerase chain reaction 6 months after the end of therapy) was obtained in 12 patients. Samples were obtained before therapy and each week for 6 weeks during therapy; HCV RNA levels were determined using quantitative bDNA.
RESULTS: At the end of week two, a viral-load drop of more than 2.20 log was observed in all the 12 patients with a sustained virological response and in none of the six other patients. When we considered the median of the viral load reduction from baseline for each week of treatment, week two appeared to be the time point most predictive of a sustained viral response (positive predictive value 83%; negative predictive value 92%).
CONCLUSION: During treatment with interferon plus ribavirin in relapsed hepatitis C patients, viral kinetics showed that the second week of treatment appeared to be the time point most predictive of a sustained viral response.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14501613     DOI: 10.1097/01.meg.0000085472.12407.49

Source DB:  PubMed          Journal:  Eur J Gastroenterol Hepatol        ISSN: 0954-691X            Impact factor:   2.566


  1 in total

1.  Kinetics of hepatitis C virus RNA load during pegylated interferon alpha-2a and ribavirin treatment in naïve genotype 1 patients.

Authors:  Denis Ouzan; Hacène Khiri; Guillaume Pénaranda; Hélène Joly; Philippe Halfon
Journal:  Comp Hepatol       Date:  2005-12-21
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.